Natixis Ardelyx, Inc. Transaction History
Natixis
- $16 Billion
- Q4 2024
A detailed history of Natixis transactions in Ardelyx, Inc. stock. As of the latest transaction made, Natixis holds 93,764 shares of ARDX stock, worth $472,570. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,764Holding current value
$472,570% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ARDX
# of Institutions
233Shares Held
150MCall Options Held
1.54MPut Options Held
3.08M-
Janus Henderson Group PLC London, X024.4MShares$123 Million0.07% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$88.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.4MShares$72.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.6MShares$58.4 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C310.3MShares$52.1 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $779M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...